Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 13
---
 These and other
factors could cause our future performance to differ materially from our assumptions and estimates. See “Cautionary Note Regarding Forward-Looking Statements.”

<div align='center'>WEBSITE DISCLAIMER</div>

We maintain a public website
at https://www.biodexapharma.com and use our website as a route channel of distribution of company information, including press releases
and presentations. Our website includes an “Investors” section through which we make available, free of charge, our Annual
Report on Form 20-F, Reports on Form 6-K, as well as any amendments to those reports filed or furnished pursuant to the Exchange Act as
soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Accordingly, investors should
monitor our website in addition to following press releases, filings with the SEC and public conference calls and webcasts.

None of the information
provided on our website, in our press releases or public conference calls and webcasts or through social media is incorporated into, or
deemed to be part of, this prospectus or any other report or document we file with the SEC, and any references to such website is intended
to be inactive textual references only.

| 3 |

PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before deciding to invest in our securities, you should read this entire prospectus and the documents incorporated by reference herein and therein carefully, including our financial statements and related notes, the information in the section “Risk Factors,” “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference.” Company Overview We are a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, including familial adenomatous polyposis, or FAP, non-muscle invasive bladder cancer, or NMIBC, type 1 diabetes, or T1D, and rare/orphan cancers of the brain. In April 2024 we licensed eRapa, a proprietary formulation of rapamycin, from Rapamycin Holdings, Inc. d/b/a Emtora Biosciences, Inc., or Emtora. Rapamycin is an mTOR inhibitor. As a central regulator of cell metabolism, growth, proliferation and survival, the mTOR pathway is activated during various cellular processes including tumor formation and angiogenesis. Through the use